Literature DB >> 10448868

Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells.

R Yamanaka1, R Tanaka, S Yoshida, T Saitoh, K Fujita, H Naganuma.   

Abstract

Human glioma cell line, Onda 10 produces TGF-beta1. TGF-beta1 has a biological role for the immunosuppression of the host. We have investigated whether suppression of TGF-beta1 on human glioma cell enhanced the susceptibility to lymphokine-activated killer (LAK) cells. In vitro, susceptibility to LAK cells on Onda 10 cell is augmented by retroviral gene transfection with antisense TGF-beta1. Nude mice bearing Onda 10 cells transduced with antisense TGF-beta1 gene has a longer life span compared to mice carrying that of sense TGF-beta1 gene or vector alone. The cytotoxic activity of LAK cells induced from spleen cells of mice carrying antisense TGF-beta1 gene transduced cells is higher against Onda 10 cell than that of LAK cells from mice carrying vector alone transduced cells. Also, antisense TGF-beta1 gene transduced cells are much more sensitive to LAK cells compared to Onda 10. These suggest that the augmented host systemic immunity in mice is one of the mechanisms of the reduced tumorigenicity of antisense TGF-beta1 gene transduced cells and that the increased systemic immunity could be ascribed to the increased immunogenicity of the tumor cells. The gene therapy for malignant glioma with antisense TGF-beta1 gene is expected to be promising.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448868     DOI: 10.1023/a:1006289901702

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Transforming growth factors type beta 1 and beta 2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-gamma and tumor necrosis factor-alpha.

Authors:  H J Schluesener
Journal:  J Neuroimmunol       Date:  1990-04       Impact factor: 3.478

2.  Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector.

Authors:  M Feng; W H Jackson; C K Goldman; C Rancourt; M Wang; S K Dusing; G Siegal; D T Curiel
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

3.  Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

Authors:  M C Kuppner; M F Hamou; Y Sawamura; S Bodmer; N de Tribolet
Journal:  J Neurosurg       Date:  1989-08       Impact factor: 5.115

4.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors:  G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

5.  TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.

Authors:  B Jin; J L Scott; M A Vadas; G F Burns
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

6.  The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

Authors:  P Jachimczak; U Bogdahn; J Schneider; C Behl; J Meixensberger; R Apfel; R Dörries; K H Schlingensiepen; W Brysch
Journal:  J Neurosurg       Date:  1993-06       Impact factor: 5.115

7.  Growth inhibition of human glioma cells modulated by retrovirus gene transfection with antisense IL-8.

Authors:  R Yamanaka; R Tanaka; S Yoshida; T Saitoh; K Fujita
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Improved bioassay for the detection of transforming growth factor-beta 1 and beta 2 in malignant gliomas.

Authors:  H Naganuma; A Sasaki; E Satoh; T Sakihama; K Tasaka; H Nukui
Journal:  Neurol Med Chir (Tokyo)       Date:  1994-03       Impact factor: 1.742

9.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family.

Authors:  R de Martin; B Haendler; R Hofer-Warbinek; H Gaugitsch; M Wrann; H Schlüsener; J M Seifert; S Bodmer; A Fontana; E Hofer
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  3 in total

Review 1.  Current immunotherapeutic strategies for central nervous system tumors.

Authors:  Medina C Kushen; Adam M Sonabend; Maciej S Lesniak
Journal:  Surg Oncol Clin N Am       Date:  2007-10       Impact factor: 3.495

2.  Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Authors:  Timothy F Witham; Lorissa Villa; Tianbing Yang; Ian F Pollack; Hideho Okada; Paul D Robbins; William H Chambers
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

3.  Autologous adjuvant linked fibroblasts induce anti-glioma immunity: implications for development of a glioma vaccine.

Authors:  Andrew T Parsa; John I Miller; Arnold E Eggers; Alfred T Ogden; Richard C Anderson; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.